CytoDyn, Inc. (OTC: CYDY)
Next Super Stock investor conference presentation 8/15/2019
CytoDyn, Inc. (OTC: CYDY) NEXT SUPER STOCK investor conference presentation
Healthcare
CytoDyn (OTC: CYDY) Reports Continued Positive Clinical Data on its Phase 1b/2 mTNBC and Expanded Access Studies for MBC Ahead of Breakthrough Therapy Designation Decision From the FDA
VANCOUVER, Washington, Feb. 14, 2020 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today continued positive […]
Healthcare
CytoDyn (OTC: CYDY) Treats First Patient in Phase 1b/2 Clinical Trial with Leronlimab (PRO 140) for Patients with Treatment-Naive, Metastatic Triple-Negative Breast Cancer
VANCOUVER, Washington, Sept. 27, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications announced today the […]
Healthcare
CytoDyn (OTC: CYDY) Submits 510(k) Pre-Submission Application to U.S. FDA for ProstaGene(TM) Prognostic Test
Dr. Richard Pestell, who leads CytoDyn’s cancer, NASH and GvHD programs, recently named to The Order of Australia, established by Queen Elizabeth II VANCOUVER, Washington, June 19, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the […]